TY - JOUR
T1 - A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
AU - Sanchez-Felipe, Lorena
AU - Vercruysse, Thomas
AU - Sharma, Sapna
AU - Ma, Ji
AU - Lemmens, Viktor
AU - Van Looveren, Dominique
AU - Arkalagud Javarappa, Mahadesh Prasad
AU - Boudewijns, Robbert
AU - Malengier-Devlies, Bert
AU - Liesenborghs, Laurens
AU - Kaptein, Suzanne J.F.
AU - De Keyzer, Carolien
AU - Bervoets, Lindsey
AU - Debaveye, Sarah
AU - Rasulova, Madina
AU - Seldeslachts, Laura
AU - Li, Li Hsin
AU - Jansen, Sander
AU - Yakass, Michael Bright
AU - Verstrepen, Babs E.
AU - Böszörményi, Kinga P.
AU - Kiemenyi-Kayere, Gwendoline
AU - van Driel, Nikki
AU - Quaye, Osbourne
AU - Zhang, Xin
AU - ter Horst, Sebastiaan
AU - Mishra, Niraj
AU - Deboutte, Ward
AU - Matthijnssens, Jelle
AU - Coelmont, Lotte
AU - Vandermeulen, Corinne
AU - Heylen, Elisabeth
AU - Vergote, Valentijn
AU - Schols, Dominique
AU - Wang, Zhongde
AU - Bogers, Willy
AU - Kuiken, Thijs
AU - Verschoor, Ernst
AU - Cawthorne, Christopher
AU - Van Laere, Koen
AU - Opdenakker, Ghislain
AU - Vande Velde, Greetje
AU - Weynand, Birgit
AU - Teuwen, Dirk E.
AU - Matthys, Patrick
AU - Neyts, Johan
AU - Jan Thibaut, Hendrik
AU - Dallmeier, Kai
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/2/11
Y1 - 2021/2/11
N2 - The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response1. Here we describe the development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike antigen. We assess vaccine safety, immunogenicity and efficacy in several animal models. YF-S0 has an excellent safety profile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and—concomitantly—protective immunity against yellow fever virus. Humoral immunity is complemented by a cellular immune response with favourable T helper 1 polarization, as profiled in mice. In a hamster model2 and in macaques, YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose conferred protection from lung disease in most of the vaccinated hamsters within as little as 10 days. Taken together, the quality of the immune responses triggered and the rapid kinetics by which protective immunity can be attained after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.
AB - The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response1. Here we describe the development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike antigen. We assess vaccine safety, immunogenicity and efficacy in several animal models. YF-S0 has an excellent safety profile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and—concomitantly—protective immunity against yellow fever virus. Humoral immunity is complemented by a cellular immune response with favourable T helper 1 polarization, as profiled in mice. In a hamster model2 and in macaques, YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose conferred protection from lung disease in most of the vaccinated hamsters within as little as 10 days. Taken together, the quality of the immune responses triggered and the rapid kinetics by which protective immunity can be attained after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.
UR - http://www.scopus.com/inward/record.url?scp=85096959421&partnerID=8YFLogxK
U2 - 10.1038/s41586-020-3035-9
DO - 10.1038/s41586-020-3035-9
M3 - Article
C2 - 33260195
AN - SCOPUS:85096959421
SN - 0028-0836
VL - 590
SP - 320
EP - 325
JO - Nature
JF - Nature
IS - 7845
ER -